NASDAQ:FORA Forian (FORA) Stock Price, News & Analysis → Protect Your Bank Account Before It’s Too Late (From Weiss Ratings) (Ad) Free FORA Stock Alerts $2.77 +0.02 (+0.73%) (As of 01:03 PM ET) Add Compare Share Share Today's Range$2.75▼$2.8550-Day Range$2.46▼$3.6452-Week Range$1.85▼$4.15Volume3,697 shsAverage Volume23,927 shsMarket Capitalization$86.26 millionP/E Ratio8.39Dividend YieldN/APrice Target$7.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Forian alerts: Email Address Forian MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside176.8% Upside$7.67 Price TargetShort InterestHealthy1.13% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.72Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.19 out of 5 starsMedical Sector383rd out of 928 stocksHealth Information Services Industry1st out of 2 stocks 3.5 Analyst's Opinion Consensus RatingForian has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageForian has only been the subject of 1 research reports in the past 90 days.Read more about Forian's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.13% of the float of Forian has been sold short.Short Interest Ratio / Days to CoverForian has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Forian has recently decreased by 8.44%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldForian does not currently pay a dividend.Dividend GrowthForian does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FORA. Previous Next 2.6 News and Social Media Coverage News SentimentForian has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Forian this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for FORA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Forian insiders have not sold or bought any company stock.Percentage Held by Insiders31.30% of the stock of Forian is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 19.25% of the stock of Forian is held by institutions.Read more about Forian's insider trading history. Previous Next 1.3 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Forian is 8.39, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 135.61.Price to Earnings Ratio vs. SectorThe P/E ratio of Forian is 8.39, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 135.66.Read more about Forian's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Forian Stock (NASDAQ:FORA)Forian Inc. provides software and information solutions, proprietary data driven insights, and predictive analytics to optimize and measure the operational, clinical, and financial performance of its life science and healthcare customers. It operates through three segments: Information & Software, Services, and Other. The company's products include BioTrack, a vertically integrated point of sale, manufacturing, delivery, and cultivator software solution for dispensaries, cultivators, manufacturers, and distributors; and Cannalytics, a Software as a Service based analytics solution that provides customers with a presentation of business performance. Its products also comprise BioTrack seed-to-sale compliance traceability platform, which is used to manage the tracking and tracing of various cannabis products from cultivation to sale; and BioTrack State Traceability & Enforcement Monitoring System to ensure transparency and accountability throughout cannabis supply chain. In addition, the company offers security monitoring and web marketing services. Forian Inc. was incorporated in 2020 and is headquartered in Newtown, Pennsylvania. Forian Inc.Read More FORA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FORA Stock News HeadlinesMay 15 at 8:09 AM | finance.yahoo.comForian Inc (FORA) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges and ...May 14 at 5:08 PM | finance.yahoo.comForian Inc. Announces First Quarter 2024 Financial ResultsMay 10, 2024 | businesswire.comVerticalScope to Participate in Upcoming Investor Conferences in May and June 2024May 7, 2024 | businesswire.comVerticalScope Delivers 14% Revenue Growth, $5.2 Million in Free Cash Flow, for First Quarter of 2024May 1, 2024 | brownswire.usatoday.comProjected Browns' 53-man roster after the 2024 NFL draftMay 1, 2024 | businesswire.comVerticalScope Partners with The Trade Desk to Integrate OpenPass and OpenPathMay 1, 2024 | msn.com2024 Tony Award nominations: LISTMay 1, 2024 | msn.comReceiver Ja'Kobi Lane earned high marks in USC spring football campMay 1, 2024 | finance.yahoo.comForian Inc. to Announce First Quarter 2024 Results on May 14, 2024May 1, 2024 | msn.comNow You Know: Bonita YMCA Community Impact Campaign continuesApril 30, 2024 | chicago.suntimes.comChicago productions on Broadway among 2024 Tony Award nominationsApril 30, 2024 | msn.com“Hell’s Kitchen” y “Stereophonic” encabezan las nominaciones a los TonyApril 30, 2024 | msn.com'Hell's Kitchen' And 'Stereophonic' Lead 2024 Tony Award NominationsApril 30, 2024 | investorplace.com7 Multibagger Growth Stocks to Buy to Defy the DowntrendApril 30, 2024 | msn.comBrowns 53 man roster: Where do things stand post-NFL Draft?April 29, 2024 | msn.comBrowns' way-too-early 53-man roster projection: Cleveland forced to cut multiple former draft picksApril 29, 2024 | msn.comBills 2024 NFL Draft grades for every pickApril 28, 2024 | sports.yahoo.comCleveland Browns depth chart projection following the 2024 NFL draftApril 27, 2024 | msn.com‘Illinoise' Broadway Review: Sufjan Stevens Masterpiece Album Dances Triumphantly On StageApril 27, 2024 | msn.comReviewing Browns GM Andrew Berry’s drafts: Who hit, who missed and who still has a chance?April 26, 2024 | usatoday.comBrowns 2024 depth chart: How Cleveland's roster shapes up ahead of 2024 NFL DraftApril 23, 2024 | msn.com‘Patriots' Broadway Review: Peter Morgan Takes On Putin, Polonium & Power PlaysApril 18, 2024 | msn.com2025 Maserati GranCabrio Folgore EV Droptop Forecasts Sunny Days AheadApril 15, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: TELA Bio (TELA), Petmed Express (PETS)April 14, 2024 | globenewswire.comForian Inc. Announces the Passing of Director Martin J. WygodSee More Headlines Receive FORA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Forian and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today5/15/2024Next Earnings (Estimated)8/08/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Health Information Services Sub-IndustryN/A Current SymbolNASDAQ:FORA CUSIPN/A CIK1829280 Webforian.com Phone+17203285372FaxN/AEmployees102Year FoundedN/APrice Target and Rating Average Stock Price Target$7.67 High Stock Price Target$13.00 Low Stock Price Target$5.00 Potential Upside/Downside+178.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio8.33 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$20.48 million Price / Sales4.18 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares31,140,000Free FloatN/AMarket Cap$85.64 million OptionableOptionable Beta1.11 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Michael Vesey (Age 62)Chief Financial Officer Comp: $457kMr. Edward Francis Spaniel Jr. (Age 54)Executive VP, General Counsel & Secretary Comp: $395.8kMr. Max C. Wygod (Age 36)Co-Founder, CEO, President & Executive Chairman of the Board Comp: $46.88kMr. Adam H. Dublin (Age 58)Co-Founder, Chief Strategy Officer & Director Comp: $113.7kMr. Jason HoldenVice President of Corporate DevelopmentRebecca AdamsVice President of Human ResourcesPaul ReuscherChief Commercial OfficerMore ExecutivesKey CompetitorsARYA Sciences Acquisition Corp IVNASDAQ:ARYDProtalix BioTherapeuticsNYSE:PLXSpero TherapeuticsNASDAQ:SPROIMACNASDAQ:IMACSensus HealthcareNASDAQ:SRTSView All CompetitorsInsiders & InstitutionsStaley Capital Advisers Inc.Sold 8,003 shares on 5/6/2024Ownership: 3.533%Martin J WygodBought 1,700 shares on 10/4/2023Total: $4,046.00 ($2.38/share)Martin J WygodBought 4,565 shares on 5/30/2023Total: $10,910.35 ($2.39/share)Martin J WygodBought 3,000 shares on 5/25/2023Total: $7,020.00 ($2.34/share)Martin J WygodBought 5,999 shares on 5/23/2023Total: $14,277.62 ($2.38/share)View All Insider TransactionsView All Institutional Transactions FORA Stock Analysis - Frequently Asked Questions Should I buy or sell Forian stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Forian in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FORA shares. View FORA analyst ratings or view top-rated stocks. What is Forian's stock price target for 2024? 4 brokerages have issued 12 month price objectives for Forian's stock. Their FORA share price targets range from $5.00 to $13.00. On average, they expect the company's share price to reach $7.67 in the next twelve months. This suggests a possible upside of 176.8% from the stock's current price. View analysts price targets for FORA or view top-rated stocks among Wall Street analysts. How have FORA shares performed in 2024? Forian's stock was trading at $2.93 at the beginning of 2024. Since then, FORA stock has decreased by 5.5% and is now trading at $2.77. View the best growth stocks for 2024 here. When is Forian's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our FORA earnings forecast. How were Forian's earnings last quarter? Forian Inc. (NASDAQ:FORA) announced its quarterly earnings data on Thursday, March, 28th. The company reported ($0.01) earnings per share (EPS) for the quarter. The company had revenue of $5.37 million for the quarter, compared to the consensus estimate of $5.72 million. What guidance has Forian issued on next quarter's earnings? Forian issued an update on its FY 2024 earnings guidance on Thursday, March, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $21.5 million-$23.6 million, compared to the consensus revenue estimate of $24.0 million. Who are Forian's major shareholders? Forian's stock is owned by many different retail and institutional investors. Top institutional investors include Staley Capital Advisers Inc. (3.53%). Insiders that own company stock include Jennifer Hajj, Martin J Wygod, Max C Wygod and Stanley S Trotman Jr. View institutional ownership trends. How do I buy shares of Forian? Shares of FORA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FORA) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersDoes this make you sick?Allegiance GoldTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportTrump Reveals Conspiracy Behind Fed-Controlled Digital Currency.Monetary GoldForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill PublishingTop 5 Tech Stocks to Buy for 2024Daily Market AlertsTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Forian Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
